Immunomodulation therapy alters the expression of HOXA10 and HOXA11, which would improve the implantation microenvironment in endometriosis and other inflammatory diseases that interfere with the proper regulation of the HOXA10 and HOXA11 genes. Here, HOXA10 is linked to endometriosis.